Treatment of severe acute respiratory syndrome with glucosteroids: The Guangzhou experience

Chest

Volumn 129, Issue 6, 2006, Pages 1441-1452

  Chen, Rong Chang ^a   Tang, Xiao Ping ^b   Tan, Shou Yong ^c   Liang, Bi Ling ^d   Wan, Zhuo Yue ^e   Fang, Ji Qian ^f   Zhong, Nanshan ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Institute of Infectious Diseases   (China)

^c Guangzhou Chest Hospital   (China)

^d SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^e GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^f SUN YAT SEN UNIVERSITY   (China)

Author keywords

Complication; Corticosteroid; Mortality; SARS

Indexed keywords

CORTICOSTEROID;

ABNORMAL RESPIRATORY SOUND; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE; ARTICLE; ASSISTED VENTILATION; CHINA; CORTICOSTEROID THERAPY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INTENSIVE CARE; LENGTH OF STAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MORBIDITY; OXYGENATION INDEX; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RALES; RESPIRATORY TRACT INFECTION; RIGOR; SEVERE ACUTE RESPIRATORY SYNDROME; SUPERINFECTION;

EID: 33745124335     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.6.1441     Document Type: Article

References (40)

1. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967-1976
2. World Health Organization. SARS: cumulative number of reported probable cases. Available at: www.who.int/csr/sars/country/en/. Accessed January 24, 2004
3. Hui DS, Sung JJ. Treatment of severe acute respiratory syndrome. Chest 2004; 126:670-674
4. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003; 52(Pt 8):715-720
5. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003; 361:1615-1617
6. Ho JC, Ooi GC, Mok TY, et al. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 2003; 168:1449-1456
7. Meng QH, Dong PL, Guo YB, et al. Use of glucocorticoid in treatment of severe acute respiratory syndrome cases. Zhonghua Yu Fang Yi Xue Za Zhi 2003; 37:233-235
8. Xiao JZ, Ma L, Gao J, et al. Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy. Chin J Intern Med 2004; 43:179-182
9. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004; 59:414-420
10. Zhong NS. Management and prevention of SARS in China. Phil Trans R Soc Lond B Biol Sci 2004; 359:1115-1116
11. Cheng VC, Tang BS, Wu AK, et al. Medical treatment of viral pneumonia including SARS in immunocompetent adult. J Infect 2004; 49:262-273
12. Tsang K, Zhong NS. SARS: phannacotherapy. Respirology 2003; 8(Suppl):25-30
13. Mishra S, Lee WM, Bressler B, et al. High dose intravenous methylprednisolone in the treatment of severe acute respiratory syndrome. Can Respir J 2004; 11:311-312
14. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348:1986-1994
15. WHO. Use of laboratory methods for SARS diagnosis. Available at: www.who.int/csr/sars/labmethods/en/. Accessed May 4, 2006
16. Wu EH, Li GX, Guo JY, et al. Diagnostic Radiology 1st ed. Beijing, China: People's Medical Publishing House, 1984; 54
17. Zheng ZG, Chen RC, Li YM, et al. The clinical characteristics of secondary infections of lower respiratory tract in severe acute respiratory syndrome. Chin J Respir Crit Care Med 2003; 2:270-274
18. Hong J, Davis JM. Nosocomial infections and nosocomial pneumonia. Am J Surg 1996; 172:338-378
19. Chinese Medical Association. Guidelines for management of atypical pneumonia (SARS). Natl Med J China 2003; 83:1731-1752
20. Tian Q, Liu YN, Xie LX, et al. Comparative study of clinical characteristics and prognosis of clinically diagnosed SARS patients with positive and negative serum SARS coronavirus-specific antibodies test. Natl Med J China 2004; 84:642-645
21. Gao Y, Shao YX, Yi Y, et al. A preliminary study of serum antibody level in SARS patients. Chin J Virol 2003; 19:203-204
22. Chen RC. Severe acute respiratory syndrome (SARS): a challenge for diagnosis and treatment. Chin J Emerg Med 2003; 12:366-368
23. Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet 2003; 362:1353-1358
24. Li XW, Jiang RM, Guo JZ. Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report. Chin J Intern Med 2003; 42:378-381
25. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 2004; 31:304-309
26. Tsang OT, Chau TN, Choi KW, et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 2003; 9:1381-1387
27. Modig J, Borg T. High dose methylprednisolone in a porcine model of ARDS induced by endotoxemia. Acta Chir Scand 1985; (Suppl)526:94-103
28. Luce JM, Montgomery AB, Marks JD, et al. Ineffectiveness of high dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988; 138:62-68
29. Bernard GR, Luce JM, Sprung CL, et al. High dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 31:1565-1570
30. Meduri GU, Tolley EA, Chrousos GP, et al. Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 165:983-991
31. Shinozaki M. Respiratory and cadiovascular management of septic ALI-ARDS and shock. Nippon Rinsho 2004; 62:2301-2307
32. Meduri GU, Headley S, Kohler G, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS; plasma IL-1 β and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995; 107:1062-1073
33. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767-1772
34. Jiang Y, Xu J, Zhou C, et al. Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. Am J Respir Crit Care Med 2005; 171:850-857
35. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol 2004; 136:95-103
36. Jones BM, Peiris JSM, Wong PC, et al. Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome treated with ribavirin and steroids. Clin Exp Immunol 2004; 135:467-473
37. Shen J, Liang BL, Zeng QS, et al. Report on the investigation of lower extremity osteonecrosis with magnetic resonance imaging in recovered severe acute respiratory syndrome in Guangzhou. Natl Med J China 2004; 84:1814-1817
38. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. Radiology 2005; 235:168-175
39. Li YM, Wang SX, Gao HS, et al. Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence. Natl Med J China 2004; 84:1348-1353
40. Hong N, Du XK. Avascular necrosis of bone in severe acute respiratory syndrome. Clin Radiol 2004; 59:602-608